Provention Bio logo
Provention Bio PRVB

Annual report 2022
added 03-29-2023

report update icon

Provention Bio Income Statement 2011-2026 | PRVB

Annual Income Statement Provention Bio

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.79 B 355 M 889 M 645 M 51.3 M - - - - - - -

Shares

74.7 M 63.1 M 52.5 M 40.7 M 22.4 M - - - - - - -

Historical Prices

23.9 5.62 16.9 14.9 1.77 - - - - - - -

Net Income

-114 M -114 M -98.6 M -43.3 M -26.5 M -9.13 M - - - - - -

Revenue

12.9 M 1.4 M - - - - - - - - - -

Operating Income

-128 M -116 M -99.7 M -44.4 M -26.8 M -9.14 M - - - - - -

Interest Expense

1.04 M - - - - - - - - - - -

EBITDA

-128 M -115 M -99.7 M -44.4 M -26.3 M -9.01 M - - - - - -

Operating Expenses

141 M 117 M 99.7 M 44.4 M 26.8 M - - - - - - -

General and Administrative Expenses

64.1 M 47.3 M 33.3 M 8.01 M 4.16 M 1.46 M - - - - - -

All numbers in USD currency

Quarterly Income Statement Provention Bio

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 83.1 M - 63.4 M 63.4 M 63.4 M 63.4 M 62.3 M 56.5 M 56.3 M 49.2 M 47.7 M 47.7 M 40.5 K 37.4 K 37.4 K 37.4 M 32 M 10 M 10 M 10 M 10 M 9.47 M - 7.64 M - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- -28.6 M - -22 M - -27 M -29.1 M -32.4 M - -31.3 M -22.1 M -12.6 M - -9.77 M -12 M -11 M - -5.39 M -10.3 M -5.06 M - -1.36 M -4.04 M - -165 K - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- 756 K - 580 K - 678 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -29.1 M - -29.1 M - -27.1 M -30.2 M -32.5 M - -31.4 M -22.8 M -12.9 M - -9.97 M -12.3 M -11.3 M - -5.41 M -10.2 M -5.04 M - -1.38 M -3.99 M - -165 K - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 255 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- -29 M - -28.9 M - -27 M -30.1 M -32.4 M - -31.4 M -22.8 M -12.9 M - -9.97 M -12.3 M -11.3 M - -5.41 M -10.2 M -5.04 M - -1.38 M -3.99 M - -165 K - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- 29.8 M - 29.7 M - 27.8 M 30.2 M 32.5 M - 31.4 M 22.8 M 12.9 M - 9.97 M 12.3 M 11.3 M - 5.41 M 10.2 M 5.04 M - 1.38 M 3.99 M - 165 K - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- 13.5 M - 12.3 M - 10 M 13.2 M 12.8 M - 9.75 M 7.76 M 3.78 M - 2.65 M 1.71 M 1.24 M - 1.27 M 1 M 653 K - 488 K 256 K - 165 K - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Provention Bio (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 18.06 - $ 28.2 B japanJapan
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.44 -0.46 % $ 909 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Protara Therapeutics Protara Therapeutics
TARA
$ 5.03 -3.08 % $ 215 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 67.0 -0.3 % $ 2.8 B usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Theravance Biopharma Theravance Biopharma
TBPH
$ 14.9 -1.91 % $ 750 M cayman-islandsCayman-islands
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.2 -6.97 % $ 306 M britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 51.31 -2.65 % $ 8.08 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 14.64 -2.2 % $ 574 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 1.07 -2.29 % $ 21.9 M israelIsrael
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 28.76 -3.43 % $ 32.9 B israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Equillium Equillium
EQ
$ 2.03 -1.46 % $ 116 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 23.81 1.51 % $ 641 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 46.38 -2.45 % $ 4.17 B schweizSchweiz